• Merus (MRUS) Interim Phase 1/2 Results of MCLA-117 for Acute Myeloid Leukemia

       (0 reviews)

    Biotech_Forecast
    Clinical and Regulatory
    Event Type: Phase 1/2 Results
    Timing: Q4 2017
    Designation(s): None

    This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Oncology
    Indication: Acute Myeloid Leukemia
    Lead Indication?: No
    Treatment Name: MCLA-117

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Merus
    Stock Symbol: MRUS
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://ir.merus.nl/phoenix.zhtml?c=254206&p=RssLanding&cat=news&id=2193638
    Partnership: No

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

     

    Quote

    Upcoming Milestones

    • By the end of 2016, Merus expects to report interim results from Part 2 of a Phase 1/2 clinical trial of MCLA-128 in breast cancer.
    • Also by the end of 2016, Merus expects to file an Investigational New Drug application with the U.S. Food and Drug Administration for a Phase 1/2 trial of MCLA-128.
    • During the second half of 2017, Merus expects to report topline data from its Phase 1/2 monotherapy trial of MCLA-128 in patients with solid tumors in multiple indications.
    • By the end of 2017, Merus expects to report interim results from Part 1 of its Phase 1/2 clinical trial evaluating MCLA-117 in patients with AML.

     

     

     


      Report Event


    User Feedback

    There are no reviews to display.